Bank of America’s Ibere Pharmaceuticals IBER Stock Holding History

Bank of America’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-320,000	Closed	-$3.23M	–	8586
2022 Q4	$3.23M	Hold	320,000	–	–	﹤0.01%	3808
2022 Q3	$3.17M	Hold	320,000	–	–	﹤0.01%	3843
2022 Q2	$3.14M	Hold	320,000	–	–	﹤0.01%	3873
2022 Q1	$3.14M	Buy	+320,000	New	+$3.12M	﹤0.01%	4124

Bank of America's IBER Position: Q1 2023 in Review

Bank of America sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 320,000 shares — an estimated $3.23M sold.

Bank of America first reported a position in IBER in Q1 2022 and held it in 4 quarters. The position peaked at $3.23M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Bank of America reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Bank of America sold 320,000 Ibere Pharmaceuticals shares in Q1 2023, an estimated $3.23M.
Bank of America first reported a position in Ibere Pharmaceuticals in Q1 2022 and held it in 4 quarters.
Bank of America's Ibere Pharmaceuticals position peaked at $3.23M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Bank of America's 13F filing for Q1 2023, filed 12 May 2023.